Eurocine Vaccines AB (publ) reported earnings results for the fourth quarter and full year ended June 30, 2023. For the fourth quarter, the company reported net loss was SEK 3.09 million compared to SEK 5.19 million a year ago. Basic loss per share from continuing operations was SEK 0.111 compared to SEK 0.302 a year ago. Diluted loss per share from continuing operations was SEK 0.111 compared to SEK 0.302 a year ago.
For the full year, revenue was SEK 0.005 million compared to SEK 0.07 million a year ago. Net loss was SEK 18.35 million compared to SEK 20.15 million a year ago. Basic loss per share from continuing operations was SEK 0.758 compared to SEK 1.4 a year ago. Diluted loss per share from continuing operations was SEK 0.758 compared to SEK 1.4 a year ago.